Entry Information

PART 1: PERSONAL PARTICULARS

Name

ALEXANDRA ROSIE PAUL

Title

Dr

Gender

Female

Recent Photo

Recent Photo

Date of Birth

22/10/1994

Place of Birth

United Kingdom

Type of Identity Document Held

Hong Kong Identity Card

HKID / Passport Number

f6268

Nationality

Others

Other

BRITISH

PART 2: CONTACT INFORMATION

Email Address

Email hidden; Javascript is required.

Contact Phone Number

+85254817809

Address

9F FELICITY BUILDING, 38 PEEL STREET, CENTRAL
HONG KONG
Hong Kong

PART 3: FORUM INTEREST

First Discipline to be Joined

Life Science and Medicine

Second Discipline to be Joined

Life Science and Medicine

Statement of Purpose to Join the Forum (max. 200 words)

I wish to join the Hong Kong Laureate Forum as I am passionate about interdisciplinary, innovative and diverse cross-cultural science. I am excited to interact and network with 200 young scientists from across the world, as I believe this is the best way science is done. I am eager to hear and learn from the Shaw Laureates, their great knowledge will have a huge impact on all young scientists, I am always aiming to learn from well-established scientists, so I believe attending this forum will align with this goal. I hope to bring a unique point of view, experience and research to the presentations and discussions. It would be a privilege to present my research in front of these established scientists and I hope to gain insightful feedback about how to improve my projects. I aim to represent my university and research team to a high standard.

PART 4: ACADEMIC AND/OR RESEARCH INFORMATION

Academic Level / Position

Postdoc

Academic Subject / Research Field

Pharmaceutical Chemistry and Nanomedicine Drug Delivery

Current Affiliated University / Institution / Organisation

The University of Hong Kong

Location

Department of Pharmacology and Pharmacy

First Academic or Research Referee *

First Referee Name

Prof Khuloud Al-Jamal

First Referee University

The University of Hong Kong

First Referee Position

Head of Department of Pharmacology and Pharmacy

First Referee Email Address

Email hidden; Javascript is required.

Second Academic or Research Referee

Second Referee Name

Dr Christopher Serpell

Second Referee University

University College London

Second Referee Position

Associate Professor of Drug Discovery

Second Referee Email Address

Email hidden; Javascript is required.

Award(s) and/or Scientific Accomplishment(s) (if any) (max. 100 words)

Research Talent Hub Postdoctoral Award, funded by the Innovation and Technology Fund,
The Government of the Hong Kong Special Administrative Region (Feb 2025- Dec 2026)
Top Poster Award, Controlled Release Society Annual Meeting & Exposition, Bologna, Italy (2024)
CW Maplethorpe Research and Teaching Fellowship, The University of London, UK (2022-2024)
Vice Chancellor PhD Scholarship, University of Kent, UK (2018-2021)
Royal Society of Chemistry, Researcher Development and Travel Grant, Awarded £500 (2024)
Royal Society of Chemistry, Research Enablement Grant (Co-PI), Awarded £9,980 (2021-2022)

Publication List (if any)

Publication-List-2025.pdf

Abstract of Research / Brief Description of Your Current Research Interest (max. 200 words)

Glioblastoma (GBM) is the most aggressive and lethal brain tumour in humans. GBM is still incurable due to its resistance to standard therapies and lack of effective drug carriers able to target and penetrate the tumour cells specifically. Given the poor survival rate, new therapeutic strategies are urgently needed. So far, the use of nucleic acids to block or stimulate the T-cells has also not been too successful, due to them being hard to transfect. A challenge that is faced is delivering the nucleic acid to the correct locations and loss of therapeutics to non-desirable cells. Conjugating a specific targeting agent (aptamers) to the nucleic acid could be a way to tackle this, as the targeting agent guides nucleic acid to the desired T-cell. Aptamers are single-stranded oligonucleotides that bind strongly and specifically to diverse targets. Aptamers can be targeted drug carriers, increasing efficacy and minimising side effects.
This research aims to create a therapeutic delivery system using novel T-cell targeting aptamers to improve the therapeutic effect of mOX40 being delivered to immune cells in GBM in vivo models. Delivering mOX40 to T-cells will overexpress this marker and trigger an immune response with the T-cells and other immune cells.

Would you like to present your Research in Poster Presentation Session and/or Flash Presentation?

Both Sessions

PART 5: OTHERS

Did you participate in the inaugural Hong Kong Laureate Forum?

N/A

How Did You Know About the Forum?

Professor